VIDAS® TBI Real Life Performance in Subjects With Mild Traumatic Brain Injury (mTBI)
Key facts
- Who runs it
- BioMérieux
- Where
- Detroit, Orlando, Rochester, and St Louis, United StatesSee the 5 sites
- Trial code
- Status
- Completed
- People taking part
- 903 people enrolled
- Started
- 16 May 2024
- Ended
- 12 Nov 2025
- Type of study
- Interventional
- Treatments tested
- VIDAS® TBI Test [GFAP and UCH-L1 assays]
- Record updated
- 6 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Adult subject ≥ 18 years old
- Subject with a Glasgow Coma Scale (GCS) score between 13-15 on admission
- Subject presenting to the Emergency Department for suspected mild Traumatic Brain Injury
- Subject with a non-contrast head Computed Tomography (CT) scan ordered per the clinical site's care usual care
- Blood sampling possible within 12 hours of injury (1 tube of 4-5 mL of blood)
- Subject expected to stay at least 2 hours in the ED or in a ward
- Subject with signed Informed Consent Form (ICF)
Who cannot take part
- Subject with non-traumatic neurological disorders (e.g, dementia, Parkinson's disease, multiple sclerosis, seizure disorder, brain tumors, spontaneous intracranial haematoma)
- Neurosurgery, stroke or transient ischemic attack within the last 30 days
- Subject with an active cancer
- Time of injury unknown
- Subject with penetrating head injury
- Special populations, including women with known pregnancy, prisoners, or institutionalized individuals
Where in United States
- Wayne State UniversityDetroit, United States
- Orlando HealthOrlando, United States
- Mayo ClinicRochester, United States
- University of RochesterRochester, United States
- Washington UniversitySt Louis, United States
About the trial
What the trial wants to find out
Decision Rules for an initial CT-scan in patients arriving to Emergency Department (ED) and presenting a mild traumatic brain injury could be optimized by the use of an objective parameter easily and rapidly measured. This may be the place for serum biomarkers providing a quick and accurate assessment. BioMérieux has now developed an automated assay for the measurement of serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase (UCH-L1), the VIDAS® TBI assay to fill out this unmet needs. The goal of the herein study is to generate real-world data and evidences to support the VIDAS® TBI performances.
The group in the trial
- Subjects with Mild Traumatic Brain injuryTreatment being tested
Subjects presenting to the ED within 12 hours of suspected mild head trauma and a Glasgow Score of 13-15 undergo to blood collection for VIDAS® TBI \[GFAP, UCH-L1\] testing.
Treatment: VIDAS® TBI Test [GFAP and UCH-L1 assays]
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Real-life Performance and Added Value of the VIDAS® TBI Blood Test in the Assessment of Mild Traumatic Brain Injury (mTBI), in Subjects With a Glasgow Coma Scale (GCS) Between 13-15
- Record updated
- 6 March 2026